阿爾法甘露醣儲積症市場：按治療類型、適應症和最終用戶分類 - 全球預測 2024-2030

預計2023年α-甘露醣儲積症市場規模為68.1億美元，2024年達74.9億美元，預計2030年將達到139.8億美元，複合年成長率為10.82%。

α-甘露醣儲積症的全球市場

FPNV定位矩陣

FPNV定位矩陣對於評估α甘露醣儲積症市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對阿爾法-甘露醣儲積症市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-α甘露醣儲積症市場的市場規模和預測是多少？

2-2-Alpha甘露醣儲積症市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-α甘露醣儲積症市場的技術趨勢和法律規範是什麼？

4-α甘露醣儲積症市場主要供應商的市場佔有率為何？

進入5-α甘露醣儲積症市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

• 市場動態
  • 促進因素
    • 大眾對α-甘露醣儲積症的認知有所提高
    • 加大投資建設現代化醫療基礎設施
  • 抑制因素
    • α-甘露醣儲積症治療相關的高成本
  • 機會
    • 治療罕見遺傳疾病的新型酵素替代療法
    • α-甘露醣儲積症藥物的產品核可增加
  • 任務
    • 與熟練衛生保健人員短缺相關的問題
• 市場區隔分析
• 市場趨勢分析
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範

第 6 章依治療類型分類的阿爾法甘露醣儲積症市場

• 骨髓移植
• 酵素替代療法

第7章依適應症分類的阿爾法甘露醣儲積症市場

• Ⅰ型
• II型
• Ⅲ型

第 8 章 阿爾法甘露醣儲積症市場：依最終用戶分類

• 醫院
• 專科診所

第9章美洲阿爾法甘露醣儲積症市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章亞太地區阿爾法甘露醣儲積症市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲的阿爾法甘露醣儲積症市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市場佔有率分析：按主要企業分類
• 主要企業競爭情境分析

第13章競爭產品組合

• 主要公司簡介
  • Chiesi Farmaceutici SpA
  • Cigna Corporation
  • CVS Caremark
  • Kamada Ltd.
  • Orient Europharma（M）Sdn Bhd
  • Talaris Therapeutics Inc.
• 主要產品系列

第14章附錄

• 討論指南
• 關於許可證和定價

[192 Pages Report] The Alpha Mannosidosis Market size was estimated at USD 6.81 billion in 2023 and expected to reach USD 7.49 billion in 2024, at a CAGR 10.82% to reach USD 13.98 billion by 2030.

Global Alpha Mannosidosis Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha Mannosidosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha Mannosidosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha Mannosidosis Market, highlighting leading vendors and their innovative profiles. These include Chiesi Farmaceutici S.p.A., Cigna Corporation, CVS Caremark, Kamada Ltd., Orient Europharma (M) Sdn Bhd, and Talaris Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Alpha Mannosidosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Treatment Type
  • Bone Marrow Transplant
  • Enzyme Replacement Therapy
• Indication
  • Type I
  • Type II
  • Type III
• End-User
  • Hospitals
  • Specialty Clinics
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alpha Mannosidosis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha Mannosidosis Market?

3. What are the technology trends and regulatory frameworks in the Alpha Mannosidosis Market?

4. What is the market share of the leading vendors in the Alpha Mannosidosis Market?

5. Which modes and strategic moves are suitable for entering the Alpha Mannosidosis Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Alpha Mannosidosis Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing awareness of alpha mannosidosis among population
    • 5.1.1.2. Increasing investment to develop modern healthcare infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with alpha mannosidosis treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging enzyme replacement therapy to treat rare genetic disorders
    • 5.1.3.2. Rising product approvals for alpha mannosidosis medications
  • 5.1.4. Challenges
    • 5.1.4.1. Issues associated with dearth of skilled healthcare professionals
• 5.2. Market Segmentation Analysis
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework

6. Alpha Mannosidosis Market, by Treatment Type

• 6.1. Introduction
• 6.2. Bone Marrow Transplant
• 6.3. Enzyme Replacement Therapy

7. Alpha Mannosidosis Market, by Indication

• 7.1. Introduction
• 7.2. Type I
• 7.3. Type II
• 7.4. Type III

8. Alpha Mannosidosis Market, by End-User

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Specialty Clinics

9. Americas Alpha Mannosidosis Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Alpha Mannosidosis Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Alpha Mannosidosis Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

• 13.1. Key Company Profiles
  • 13.1.1. Chiesi Farmaceutici S.p.A.
  • 13.1.2. Cigna Corporation
  • 13.1.3. CVS Caremark
  • 13.1.4. Kamada Ltd.
  • 13.1.5. Orient Europharma (M) Sdn Bhd
  • 13.1.6. Talaris Therapeutics Inc.
• 13.2. Key Product Portfolio

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. ALPHA MANNOSIDOSIS MARKET RESEARCH PROCESS
• FIGURE 2. ALPHA MANNOSIDOSIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ALPHA MANNOSIDOSIS MARKET DYNAMICS
• FIGURE 7. ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 8. ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 10. ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, 2023
• FIGURE 22. ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

• TABLE 1. ALPHA MANNOSIDOSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 6. ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 9. ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 13. ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 26. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EGYPT ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. NIGERIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. QATAR ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. QATAR ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. QATAR ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, 2023
• TABLE 143. ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 144. ALPHA MANNOSIDOSIS MARKET LICENSE & PRICING